Curated News
By: NewsRamp Editorial Staff
October 21, 2024
Stonegate Capital Partners Initiates Coverage on Sirona Biochem Corp, Highlighting Potential in Premium Skincare Market
Discuss on Reddit
LinkedIn
Substack
TelegramTLDR
- Sirona Biochem Corp's GlycoProteMim™ targets the premium skincare market, positioning the company for strong revenue growth and market share capture.
- Sirona Biochem Corp's strategy includes targeting profitability by 2025, driven by expected revenue from Allergan Aesthetic and the commercialization of GlycoProteMim™.
- Sirona Biochem Corp's partnerships and focus on premium skincare contribute to the global skincare industry, offering potential benefits for consumers and the world.
- Stonegate Capital Partners initiates coverage on Sirona Biochem Corp, highlighting the potential of GlycoProteMim™ in the premium skincare market and Sirona's growth prospects.
Impact - Why it Matters
This news matters as it sheds light on the growth potential of Sirona Biochem Corp and its innovative product, GlycoProteMim™, in the skincare industry. Investors and consumers should take note of Sirona's strategic partnerships and target for profitability by 2025, which could impact the future of premium skincare products.
Summary
Stonegate Capital Partners has initiated coverage on Sirona Biochem Corp (TSX-V:SBM) (FSE: ZSB) (OTC: SRBCF), highlighting the potential of GlycoProteMim™ in the premium skincare market. With a focus on profitability by 2025 and strategic partnerships, Sirona is poised for growth in the global skincare industry.
Source Statement
This curated news summary relied on this press release disributed by NewMediaWire. Read the source press release here, Stonegate Capital Partners Initiates Coverage on Sirona Biochem Corp, Highlighting Potential in Premium Skincare Market
